Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 5Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 4Dermatologic 1

Conditions

Lymphoma 3Leukemia 3Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × forodesine × Clear all
NCT00289549 2012-02-08

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

BioCryst Pharmaceuticals

Phase 2 Completed
8 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00501735 2012-01-23

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

BioCryst Pharmaceuticals

Phase 2 Completed
144 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00289562 2012-01-20

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

BioCryst Pharmaceuticals

Phase 1/2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma

NCT00095381 2012-01-19

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

BioCryst Pharmaceuticals

Phase 2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, T-Cell

NCT00035022 2006-01-13

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

BioCryst Pharmaceuticals

Phase 1/2 Completed
71 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡